Table 1:

Cellular Therapy Specific Trials

First Author	COG Study/Collaboration	Reference	Findings	Outcome/Follow-up Study
Yanik	ASCT0521	57	Phase 2 study of TNF blockade with etanercept for the treatment of idiopathic pneumonia syndrome (IPS). 28 IPS patients were treated and a high rate of complete responses, 71%.	Etanercept is standard of care for pediatric IPS
Pulsipher	ASCT 0431 – Ancillary analysis	7	IgH-V(D)J NGS-MRD predicted relapse and survival post-HCT better than flow MRD. Relapse 0 vs 16%, 2 yr OS 96% vs 77%	PTCTC ONC1701 (EndRAD Trial) to test radiation free conditioning in NGS MRD- patients
Wagner	BMT CTN 0501	17	Survival similar for both single vs double cord blood transplants (73% vs 65%) but better platelet recovery and less grade 3-4 GVHD with single cord	Single cord blood unit HCT preferred for children
Dvorak	ASCT1221	13	Tested BuCyMel vs BuFlu regimens in JMML patients. More complications with BuCyMel but more relapses with BuFlu.	BuCyMel remains standard of care despite more complications